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Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of
therapeutic agents into cell nuclei can be challenging. A subset of lupus autoantibodies is associated with
nucleolytic activity, and some of these antibodies are capable of nuclear penetration. We hypothesized that
such antibodies might have potential as therapeutic agents targeted towards DNA repair-deficient
malignancies. We identified the lupus autoantibody 5C6 as a cell-penetrating nucleolytic antibody and
found that 5C6 has a differential effect on a matched pair of BRCA2-proficient and deficient DLD1 colon
cancer cells. 5C6 selectively induced cH2AX in, and suppressed the growth of, the BRCA2-deficient cells.
These findings demonstrate the potential utility of 5C6 in targeted therapy for DNA repair-deficient
malignancies and strengthen the rationale for studies of additional lupus autoantibodies in order to identify
the best candidates for development as therapeutic agents. In addition, the toxic effect of 5C6 on
BRCA2-deficient cells provides further support for the hypothesis that some lupus autoantibodies
contribute to the lower risk of specific cancers associated with systemic lupus erythematosus.
S
ystemic lupus erythematosus (SLE) is an autoimmune disease in which inappropriate production of auto-
antibodies results in widespread inflammation and organ dysfunction1. A small percentage of lupus auto-
antibodies penetrate into the nuclei of living cells, and these antibodies have potential utility in molecular
therapy2. A cell-penetrating lupus anti-DNA autoantibody, 3E10, has previously been developed as a vehicle for
intracellular delivery of therapeutic cargomolecules, and this approach has proven effective in vitro and in vivo3–5.
More recently we made the unexpected discovery that 3E10, by itself, inhibits DNA repair and is synthetically
lethal to cancer cells with defects inDNA repair due to BRCA2-deficiency6. An emerging area of investigation into
cell-penetrating lupus autoantibodies now focuses on their potential use as targeted therapies for cancer.
Development of tumor-selective therapies is a critical goal in cancer research. Many cancer cells harbor
deficiencies in DNA repair and are more sensitive to DNA damage than normal cells7, and agents that localize
to cell nuclei and inhibit DNA repair or damage DNA therefore have potential as targeted therapies for DNA
repair-deficientmalignancies. Effective delivery of therapeutic agents to cell nuclei is challenging, but the subset of
naturally occurring lupus autoantibodies that penetrate into cell nuclei may be well suited to this role. Based on
our discovery that 3E10 inhibits DNA repair and is toxic to BRCA2-deficient cells, we hypothesized that
additional lupus autoantibodies may have similar potential for use as targeted cancer therapies.
Importantly, while 3E10 does not appear to directly damage DNA, cell-penetrating nucleolytic lupus auto-
antibodies have been previously reported8,9. The ability of these antibodies to directly localize into cell nuclei and
to potentially induce DNA damage makes them intriguing candidates for development as targeted therapies for
DNA repair-deficient malignancies. To the best of our knowledge the impact of a cell-penetrating nucleolytic
lupus autoantibody on cells with defects in DNA repair has not been previously tested. We therefore set out to
identify a cell-penetrating nucleolytic lupus autoantibody and test its effects on a matched pair of BRCA2-
proficient and deficient DLD1 colon cancer cells.
Results
5C6 is a nucleolytic lupus autoantibody. We screened a panel of lupus anti-DNA antibodies for nucleolytic
activity in order to identify a candidate for testing on the BRCA2-deficient cells. Anti-DNA autoantibodies
produced by hybridomas generated from the MRL-mpj/lpr mouse model of SLE10 were incubated with DNA
in vitro, and most did not significantly impact the integrity of the DNA (not shown). The IgG2a-k antibody 5C6,
however, was found to be associated with significant degradation of both single and double-strandedDNA.When
incubated withM13mp18 single-stranded DNA, 5C6 catalyzed degradation of the single-strandedDNA in a time
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and dose-dependent manner, with near complete degradation of the
single-stranded DNA by 10 minutes at doses of 1.25 mM and higher
(Fig. 1A–D). When incubated with double-stranded plasmid DNA
(pBluescript) 5C6 similarly catalyzed a time-dependent degradation
of the plasmid DNA (Fig. 1E–F). These data indicated that 5C6 is
associated with nucleolytic activity, and we therefore proceeded to
test the effects of 5C6 on cells.
5C6 penetrates into cell nuclei.We first sought to confirm that 5C6
penetrates into cell nuclei. DLD1 colon cancer cells were treated with
control media or media containing 5C6. Cells were then washed,
fixed, and immunostained for murine IgG. Propidium iodide (PI)
counterstaining allowed direct visualization of cell nuclei, and
overlay of anti-IgG and PI fluorescent images confirmed nuclear
localization by 5C6 in the DLD1 cells (Fig. 2).
5C6 has a differential impact on BRCA2-proficient and BRCA2-
deficient DLD1 cells. The effect of 5C6 on the matched pair of
BRCA2-proficient (BRCA21) and BRCA2-deficient (BRCA2-)
DLD1 cells was assessed. Cells were treated with control media or
media containing 10 mM5C6 for one hour, followed by evaluation of
the percentage of cells positive for cH2AX (amarker of DNAdouble-
strand breaks) by immunofluorescence. 5C6 did not increase the
percentage of cH2AX-positive BRCA21 cells but did increase the
percentage of cH2AX-positive BRCA2- cells approximately 5-fold
compared to control cells (2.3% versus 10.3%; p50.03) (Fig. 3A, B,
and C). The observed increase in percentage of cH2AX-positive
BRCA2- cells after treatment with 5C6 may reflect direct DNA
damage induced by 5C6, and the differential impact of 5C6 on
cH2AX expression in the BRCA21 and BRCA2- cells suggests
that defective DNA repair in the BRCA2- cells makes them more
susceptible to the effects of the 5C6 nucleolytic antibody.
5C6 selectively suppresses the growth of the BRCA2- DLD1 cells.
To confirm that 5C6 is more toxic to BRCA2- than BRCA21
cells, we tested the effect of 5C6 on the proliferation of BRCA21
and BRCA2- DLD1 cells growing as subconfluent monolayers.
BRCA21 and BRCA2- DLD1 cells were treated with control
media or media containing 10 mM 5C6. Four days later total viable
cell counts were determined. 5C6 did not significantly inhibit the
growth of the BRCA21 cells (percent growth inhibition of 2.8% 6
9). However, 5C6 significantly impaired the growth of the BRCA2-
cells (percent growth inhibition of 41% 6 8) (Fig. 3D). These results
are consistent with our finding that 5C6 selectively induced an
increase in cH2AX in BRCA2- cells and demonstrate that 5C6 is
more toxic to BRCA2- than BRCA21 cells.
5C6 induces senescence in the BRCA2-deficient DLD1 cells. To
investigate the mechanism by which 5C6 suppresses the growth of
BRCA2- DLD1 cells we examined the effect of 5C6 on membrane
integrity as a marker for apoptosis or necrosis. BRCA2- DLD1 cells
were treated with control or 10 mM 5C6 and then treated with
propidium iodide (PI). No significant increase in the percentage of
PI-positive cells in the presence of 5C6 relative to control media was
observed (Fig. 4A), which suggests that neither apoptosis nor
necrosis are the primary mechanisms responsible for the effect of
5C6 on BRCA2- cells. We therefore proceeded to test the effect of
5C6 on induction of cell senescence by examining the relative
expression of b-galactosidase (b-gal) in cells treated with 5C6. As
shown in Fig. 4B–D, 5C6 yielded a significant and dose dependent
increase in b-gal expression in the BRCA2- DLD1 cells, which
suggests that 5C6 suppresses the growth of the cells by inducing
senescence. At dose of 6.6 mM 5C6 increased the percentage of b-
gal-positive cells to 39.3% 6 1.8 compared to 16.3% 6 1.3 in cells
treated with control media.
Discussion
We have shown that a cell-penetrating nucleolytic lupus autoanti-
body, 5C6, has a differential effect on BRCA21 and BRCA2- DLD1
cells. Specifically, 5C6 induces cH2AX in BRCA2- but not BRCA21
cells and selectively suppresses the growth of the BRCA2- cells.
Mechanistically, 5C6 appears to induce senescence in the BRCA2-
cells. Senescence is a well-known response to DNA damage, and
Figure 1: | 5C6 is a nucleolytic lupus autoantibody. (A): 5C6 degrades
single-stranded DNA in a time-dependent manner. Single-stranded
M13mp18 circular DNAwas incubatedwith buffer containing 2.5 mM5C6
for 0–60 minutes, followed by visualization of DNA on an agarose gel. (B):
The percentage of M13mp18 DNA remaining after incubation with 5C6
was quantified relative to untreated M13mp18 DNA. (C): 5C6 degrades
single-stranded DNA in a dose-dependent manner. M13mp18 DNA was
incubated with buffer containing 0–2.5 mM 5C6 for 10 minutes, followed
by visualization on an agarose gel. (D): The percentage of M13mp18 DNA
remaining after incubation with 5C6 as described in C was quantified
relative to untreated M13mp18 DNA. (E): 5C6 degrades double-stranded
DNA. pBluescript double-stranded plasmid DNA was incubated with
buffer containing 6.6 mM5C6 for 0–24 hours followed by visualization on
an agarose gel. (F): The percentage of pBluescript plasmid DNA remaining
after incubation with 5C6 as described in E was quantified relative to
untreated pBluescript. C5circular conformation. L5linear conformation.
N5nicked conformation. S5supercoiled conformation. Error bars: SEM.
Figure 2: | 5C6 penetrates into DLD1 cell nuclei. DLD1 cells were treated
with control media or media containing 3.3 mM 5C6 for 1.5 hours. Cells
were then washed, fixed, and immunostained for presence of IgG, followed
by counterstaining with PI to allow visualization of the nucleus. Light and
fluorescent images under GFP and RFP filters are presented. Merged
images confirm nuclear localization by 5C6. Scale bar: 20 mm.
www.nature.com/scientificreports
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DNA damaging agents, including many chemotherapeutics, induce
senescence after prolonged exposure11–13. Taken together, the obser-
vations listed above provide strong support for the hypothesis that
5C6 penetrates cell nuclei and damages DNA, and that cells with pre-
existing defects in DNA repair due to BRCA2-deficiency are more
sensitive to this damage than cells with intact DNA repair.
We previously found that the cell-penetrating lupus anti-DNA
antibody 3E10 inhibits DNA repair and is selectively toxic to
BRCA2- cancer cells6, which revealed the possibility of using select
lupus antibodies as targeted cancer therapies. However, a key ques-
tion remained regarding whether the effect of 3E10 on BRCA2-
cancer cells was a unique phenomenon or if there are other lupus
autoantibodies that have similar or even greater potential for use in
cancer therapy.We have now answered this question by showing that
the nucleolytic lupus autoantibody 5C6 also has a selective effect on
BRCA2-deficient cancer cells.
The finding that 5C6 has a selective impact on BRCA2- cells may
also provide further insight into the unusual cancer risk profile assoc-
iated with SLE. SLE is associated with an overall increased risk of
malignancy, but lower than expected rates of tumors associated with
defects in BRCA2 such as breast, ovarian, and prostate cancers14–16.
The pathophysiology underlying this risk profile is unknown and is
likely multifactorial17,18. We previously suggested that cell-penetrating
lupus autoantibodies such as 3E10 that inhibit DNA repair might
contribute to this phenomenon by suppressing growth of BRCA2-
cells6, and our present findings now raise the possibility that nucleo-
lytic lupus autoantibodies may also contribute to inhibiting the
growth of BRCA2-associated tumors in patients with SLE. Addi-
tional epidemiologic and laboratory studies are needed before any
definitive conclusions may be drawn in this regard.
The primary significance of this work is in providing proof of
principle to support additional studies into the application of nucleo-
Figure 3: | 5C6 has a differential impact on BRCA2-proficient and deficient DLD1 cells. (A) and (B): BRCA21 and BRCA2- DLD1 cells were treated
with control media or media containing 10 mM5C6 for 1 hour. Cells were then washed, fixed, and probed for the presence of cH2AX with an Alexa-488
conjugated antibody. Light and immunofluorescence images are presented. Scale bar 5 100 mm. (C): The percentage of cH2AX-positive BRCA2- cells
after treatment with control or 5C6 was quantified. 5C6 increased the percentage of cH2AX-positive cells ,5-fold relative to control media. *p50.03
(n54). (D): 5C6 is toxic to BRCA2- DLD1 cells. BRCA21 and BRCA2- DLD1 cells in subconfluentmonolayers were treated with control media ormedia
containing 10 mM5C6 for 4 days. Cells were then harvested and counted using trypan blue. Percent growth inhibition relative to cells treated with control
was determined. Percent growth inhibition is presented. 5C6 did not notably impact the relative percentage of viable BRCA21 cells but significantly
suppressed the growth of the BRCA2- cells. *p50.01 (n56). Error bars: SEM.
Figure 4: | 5C6 induces senescence in BRCA2-deficient DLD1 cells.
(A): 5C6 does not appear to induce apoptosis or necrosis of BRCA2-DLD1
cells. Cells were treated with control media or media containing 10 mM
5C6, and cell membrane integrity was then examined by visualization of PI
uptake. No difference in PI uptake was observed between the cells treated
with control or 5C6, suggesting that apoptosis or necrosis are not the
primary mechanisms by which 5C6 is toxic to the BRCA2- cells.
(B), (C), and (D): 5C6 induces senescence in the BRCA2- DLD1 cells. Cells
were treated with control media ormedia containing 6.6 mM5C6 and were
then stained for b-gal as a marker of senescence. Representative images are
shown in B, and the percentage of b-gal-positive cells was quantified in C.
*p50.009 (n52). The impact of 5C6 on the percentage of b-gal-positive
cells was dose dependent (D).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5958 | DOI: 10.1038/srep05958 3
lytic lupus autoantibodies as targeted therapies for DNA repair-defi-
cient malignancies. A wide range of human malignancies harbor
deficiencies in DNA repair7, and this therapeutic strategy therefore
has potential for applications in the treatment of numerous tumors.
The findings presented herein also strengthen the rationale for con-
tinuing the search for lupus autoantibodies that may have even greater
and more selective effects on cancer cells. Given the diversity of
autoantibodies associated with SLE19 we are confident that additional
lupus autoantibodies with therapeutic potential await discovery.
Methods
Hybridomas and cell lines. A panel of hybridomas, including the 5C6 hybridoma,
was previously generated from the MRL-mpj/lpr lupus mouse model and DNA
binding activity was evaluated10,20. Hybridomas were maintained in serum free
hybridoma media (BD Cell MAb medium; BD Biosciences, San Jose, CA)
supplemented with 2 mM L-glutamine (Life Technologies, Carlsbad, CA).
Antibodies were harvested in hybridoma supernatants and exchange-dialyzed into
appropriate media. BRCA21 and BRCA2- DLD1 colon cancer cells (Horizon
Discovery Ltd, Cambridge, UK) were grown in RPMI 1640 (Life Technologies)
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Saint Louis, MO).
Cell-penetration assays. DLD1 cells grown on glass coverslips were treated with
control buffer or 3.3 mM 5C6 for 1.5 hours. Cells were then washed with PBS, fixed
with chilled 100% ethanol for 5 minutes, washed again with PBS, and then probed
with Alexa488-conjugated goat anti-mouse IgG antibody overnight at 4uC (Cell
Signaling, Danvers, MA). To counterstain the nucleus, PI at 1 mg/ml was added to the
cells for 30 minutes. Nuclear penetration by the antibodies was then imaged using an
EVOS fl digital fluorescence microscope (Advanced Microscopy Group, Bothell,
WA) using green fluorescent protein (GFP) filter (403 magnification; Life
Technologies).
cH2AX assays. BRCA21 and BRCA2- DLD1 cells were treated with control media or
media containing 10 mM 5C6 for one hour. Cells were then washed with PBS, fixed
with chilled 100% ethanol for 5 minutes, washed again with PBS, blocked with 1% BSA/
PBS for 45 minutes and then probed with Alexa488-conjugated anti-cH2AX antibody
overnight at 4uC (Cell Signaling). Fluorescent signal corresponding to cH2AXwas then
imaged using an EVOS fl digital fluorescence microscope using a GFP filter.
Catalytic assays. For single-stranded plasmid DNA assays, single-stranded
M13mp18 DNA (New England Biolabs, Ipswich, MA) was incubated with 0–2.5 mM
5C6 for 0–60 minutes in binding buffer (50 mM Tris-HCl, 100 mM NaCl, 10 mM
MgCl2). The reaction was terminated by the addition of 1% SDS. Samples were boiled
and then run on 1% agarose gels and stained with SYBR Gold (Life Technologies) for
30 minutes. The proportion of DNA remaining after treatment relative to untreated
M13mp18 DNA was then calculated by band densitometry using ImageJ (National
Institutes of Health, Bethesda, MA). pBluescript (Agilent Technologies, Englewood,
CO) was used in double-stranded plasmid DNA assays by incubating with 6.6 mM
5C6 for 0–24 hours in binding buffer at 37uC. Samples were then boiled, and DNA
conformations were visualized on 1% agarose gels with ethidium bromide. The
proportion of DNA remaining after treatment relative to untreated pBluescript DNA
was then calculated by band densitometry using ImageJ.
Cell growth assays.BRCA21 and BRCA2-DLD1 cells were plated in 48 well plates at
1 3 104 and allowed to adhere overnight. The cells were then treated with control
media or media containing 10 mM 5C6. Cell counts were determined four days later
by trypan blue extrusion. Percent growth inhibition was then calculated by
comparing the total number of viable cells treated with 5C6 relative to cells treated
with control media.
Propidium iodide uptake. BRCA2- DLD1 cells were plated in 96 well plates at 3 3
104 and allowed to adhere overnight. The cells were then treated with controlmedia or
media containing 10 mM 5C6 overnight at 37uC. Antibody was then removed and
cells were stained with 1 mg/ml PI for 15 minutes at room temperature. Cells were
then imaged for PI uptake using an EVOS fl digital fluorescence microscope using an
RFP filter.
Cellular senescence assay. BRCA2- DLD1 cells were plated in 12 well plates at 2 3
104 and allowed adhere overnight. The cells were then treated with media containing
0–6.6 mM 5C6. Cells were incubated at 37uC for 4 days. The Senescence-bGal
Staining Kit (Cell Signaling Technology) was used for b-gal staining. After treatment
cells were washed, fixed and stained for the presence of b-gal at pH 6.0. Cells were
then imaged (Olympus IX70, Tokyo, Japan) and percentage of b-gal positive cells
calculated.
Statistics. P values were determined by two-tailed Student’s t-test.
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